David M. Albala, MD

David M. Albala, MD

Crouse Hospital

Syracuse, New York

David M. Albala, MD, graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor toProfessor in Urology and Radiology in eight years. Ten years later, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology Fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has over 247 publications in peer-reviewed journals and has authored three textbooks in endourology and seven in general urology. He is the Editor-in-Chief of the Journal of Robotic Surgery. Dr. Albala serves on the editorial board for Medical Reviews in Urology, Current Opinions in Urology, and Urology Index and Reviews. He serves as a reviewer for eight surgical journals. He is a Visiting Professor in the Department of Urology at SUNY Downstate Health Sciences University. In addition, he was ranked among the top 2% of urologists in the world by a Stanford University study done in May 2021. At the present time, Dr. Albala is Chief of Urology at Crouse Hospital and a member of Associated Medical Professionals in Syracuse, New York. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urological surgery. His other clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH), biomarkers in prostate cancer, and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well internationally in multiple countries including India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and 23 states. He has trained 19 fellows in endourology and advanced robotic surgery. In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.


Speaker: Genomic Health
Ad Board: Cellanyx

Talks by David M. Albala, MD

Ablative Local Technologies (HIFU, Cryo, SBRT, Laser, and Other Forms of Energy)

David M. Albala, MD, provides an overview and comparison of current options for focal ablative therapy in prostate cancer treatment. He begins by briefly touching on the benefits of focal therapy as a whole, before exploring the different types of focal therapy.

Dr. Albala categorizes focal therapies into temperature-based therapies and non-temperature-based therapies. He places High Intensity Focused Ultrasound, Laser Ablation, and Cryotherapy in the temperature-based focal therapies. Radiotherapies like seed, HDR, and EBRT join Photodynamic Therapy, Radiofrequency Ablation, Electroporation, and partial prostatectomy in the non-temperature-based category.

Dr. Albala discusses the importance of weighing cancer control with preservation of function and patient QoL when considering focal therapies. He discusses the assessment process and the rate of failure for focal therapies. He underscores the process of patient selection and treatment planning prior to selecting a therapy.

He concludes by reviewing the delivery methods currently available for focal therapy. For each method, he presents the advantages, disadvantages, and ideal patient profile for each treatment.

Read More

2023 Legislative and Regulatory Issues Update

In this panel discussion, David M. Albala, MD, Ronald P. Kaufman Jr., MD, and Mara R. Holton, MD, address the pressing issue of Medicare payment cuts in urology. The speakers emphasize the importance of unified advocacy, both at the legislative level and within the urology community.

The panelists discuss the failed MIPS/MACRA program and the need for site-neutral payment reform, underscoring the urgent need for change. Additionally, they discuss the significance of PBM reform and the role it plays in curbing inflationary drug costs. They conclude the presentation with a call to action for urologists, encouraging them to engage in advocacy efforts, work together as a united front, and demand meaningful payment reform to protect the profession.

Read More

Robotic Prostatectomy: How Far Have We Come All These Years?

In this 11-minute video, David M. Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York, discusses the increasing use of robotic prostatectomy and its effectiveness today. He compares robotic prostatectomy surgery to open surgery regarding perioperative outcomes, positive surgical margins, oncological outcomes, and functional outcomes.

Read More

Integrating Theranostics Into a Group Practice

David M. Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York, discusses theranostics and the role it will play in the future of prostate cancer treatment. He explains that theranostics is a management strategy involving the integration of therapeutics and diagnostics that specifically uses targeting molecules labeled with either diagnostic radionuclides or with therapeutic radionuclides for diagnosis of and therapy for a particular malignancy. Dr. Albala states that theranostics works to overcome trial and error methods of finding “one-size-fits-all” solutions in medicine in order to produce personalized medicine. Dr. Albala also discusses PSA and PSMA, explaining that PSMA is used with different ligands such as PSMA-11 and PSMA-617 to treat specific individuals. He reviews how theranostics are used with radionuclide agents to determine localization, examine molecular biodistribution, aid in determining optimal therapeutic dosage, and monitor the patient’s response to treatment. Dr. Albala then reviews data from a trial of Lutetium-177 and PSMA-617 for metastatic castration-resistant prostate cancer that showed Lutetium-based treatment outdoing standard-of-care in median overall survival by 4 months and skeletal event occurrence by 3%. He concludes with a summary of the implications of theranostics for patient care, stating that theranostics leads to more effective disease management and eliminates unnecessary treatments, enhances diagnosis and disease staging, and reduces costs associated with suboptimal diagnostics and treatments.

Read More

The Live Primary Cell Phenotypic Test (LPCP) for Prostate Cancer

David M. Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York, discusses the experimental live primary cell phenotypic test (LPCP) for prostate cancer. He details how live, unfixed cancer cells are taken from tissue, plated out on an extracellular matrix, and grown in a single cell monolayer. The LPCP looks at 14 different biomarkers from both normal and malignant cells, and machine learning algorithms generate scores that, according to preliminary research, can accurately predict general, local, and metastatic adverse pathology potential.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -